article thumbnail

DEA Pharmacy Decision Highlights Agency’s Thinking on Expert Credibility and Testimony, as well as Red Flag Resolution

FDA Law Blog: Biosimilars

Hull A recent DEA decision revoking the registration of a Louisiana pharmacy sheds light on the Agencys approach to crediting one experts testimony over that of another expert during an administrative hearing. The hearing involved dueling expert testimony on the pharmacy standard of care in Louisiana from both DEA and the respondent.

article thumbnail

PBM executives threatened with fines for alleged perjury in House hearing

BioPharma Drive: Drug Pricing

Testimony from the heads of Express Scripts, Optum Rx and Caremark in July defending pharmacy benefit managers’ business practices could be coming back to bite them.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Respiratory Illnesses in China Not Caused by New Virus, CDC Director Testifies

Drugs.com

1, 2023 (Healthday News) -- In testimony provided Thursday to members of Congress, the head of the U.S. FRIDAY, Dec. Centers for Disease Control and Prevention said that a surge in respiratory illnesses in China is not being fueled by a new.

article thumbnail

Sanders threatens to subpoena J&J, Merck CEOs over drug prices

BioPharma Drive: Drug Pricing

The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.

article thumbnail

HP&M Counsel John Claud Provides Testimony to House Subcommittee on FDA Foreign Inspections

FDA Law Blog: Biosimilars

Mr. Claud was joined in his testimony by Mary Denigan-Macauley , a Director for Health Care at the Government Accountability Office (GAO) and Dinesh Thakur. Mr. Claud closed his testimony echoing that sentiment. Mr. Thakur is a public health advocate and a former executive at Ranbaxy Laboratories in India.

article thumbnail

R&D Partnering Testimonials from Bayer, Oldcastle and Joyn Bio

Translation

The post R&D Partnering Testimonials from Bayer, Oldcastle and Joyn Bio appeared first on Translation | Halo Blog.

article thumbnail

Schedule III Marijuana Would Still Be Regulated Marijuana

FDA Law Blog: Biosimilars

In January a public hearing began to receive factual evidence and testimony on whether marijuana should be rescheduled. DEA published a Notice of Proposed Rulemaking (NPRM), signed by Attorney General Merrick Garland, proposing to reschedule marijuana in May 2024 that elicited over 43,500 comments.